Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.50 |
| ▸ | TDO2 | P48775 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29064053 | 0.89 | IDO1 (0.59) | IDO1TSHRHIF1ATDO2LMNA | |
| SCHEMBL11040029 | 0.81 | TSHR (0.50) | IDO1TSHRHIF1ATDO2LMNA | |
| SCHEMBL4551073 | 0.80 | TSHR (0.68) | TSHRTP53CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL11660398 | 0.79 | TSHR (0.55) | IDO1TSHRHIF1ATDO2LMNA | |
| SCHEMBL10979127 | 0.78 | CYP1A2 (0.51) | IDO1TSHRLMNAMAPK1TDP1 | |
| SCHEMBL6075401 | 0.78 | SLC6A2 (0.52) | TSHRLMNAADRB2SLC6A4SLC6A3 | |
| SCHEMBL25015977 | 0.77 | TSHR (0.52) | IDO1TSHRHIF1ATDO2LMNA | |
| SCHEMBL19576827 | 0.77 | ADRB2 (0.56) | IDO1TSHRHIF1ATDO2LMNA | |
| SCHEMBL1145586 | 0.77 | ADRB2 (0.56) | IDO1TSHRHIF1ATDO2LMNA | |
| SCHEMBL10736178 | 0.77 | TP53 (0.48) | IDO1TSHRHIF1ATDO2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115478430-B | Nuclear protection nanofiber aerogel with bionic structure and preparation method thereof | 东华大学 | 2023-10-31 | — | — | CN | claimed |
| CN-115478430-A | Bionic-structure core protection nanofiber aerogel and preparation method thereof | 东华大学 | 2022-12-16 | — | — | CN | claimed |
| CN-115478430-B | Nuclear protection nanofiber aerogel with bionic structure and preparation method thereof | 东华大学 | 2023-10-31 | — | — | CN | disclosed |
| CN-115478430-A | Bionic-structure core protection nanofiber aerogel and preparation method thereof | 东华大学 | 2022-12-16 | — | — | CN | disclosed |
| WO-2022107692-A1 | SEALING MATERIAL FOR ORGANIC EL DISPLAY ELEMENT, CURED PRODUCT OF SAID SEALING MATERIAL, AND ORGANIC EL DISPLAY DEVICE | 三井化学株式会社 | 2022-05-27 | — | — | WO | disclosed |
| US-7067538-B2 | MCP-1 receptor antagonists and methods of use thereof | WARNER-LAMBERT COMPANY, LLC (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050171163-A1 | MCP-1 receptor antagonists and methods of use thereof | BRATTON LARRY D (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1539685-A1 | MCP-1 RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | Warner-Lambert Company LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014847-A1 | MCP-1 RECEPTOR ANTAGONISTS AND METHOD OF USE THEREOF | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| US-5773437-A | UROGENITAL DISORDERS SUCH AS DYSURIA | NIPPON CHEMIPHAR CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| EP-0753514-A1 | ALKYLENEDIAMINE DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 1997-01-15 | — | — | EP | disclosed |
| US-4018926-A | Alkyl 4-[o-(substituted methyleneamino)-phenyl]-3-thioallophanate miticides and fungicides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
| US-3958007-A | FUNGICIDES, MITE OVICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-05-18 | — | — | US | disclosed |
| US-3950391-A | FUNGICIDES, MITICIDES, OVICIDES | ADAMS CHARLES D | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171163-A1 | MCP-1 receptor antagonists and methods of use thereof | CCR2, CCR1, CCL2 | IDO1 638/4885TSHR 744/4885HIF1A 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.